Alexion Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alexion Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count).
Alexion Pharmaceuticals: 162 sponsored US clinical trials, 17 recruiting.
Alexion Pharmaceuticals sponsors 162 registered US clinical trials on ClinicalTrials.gov, 17 of them currently recruiting, and 93 completed. 45 of these trials are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Paroxysmal Nocturnal Hemoglobinuria, with 5 trials.
Top-decile sponsor footprint
Alexion Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
93 of 129 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
162 total, page 4 of 4
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
NCT00401947
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
NCT00380159
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
NCT00350272
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
NCT00312039
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT00122317
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
NCT00122304
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
NCT01374360
Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT00122330
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
NCT00088179
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
NCT00040144
Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass
NCT00048308
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
NCT00040157
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 43 |
| Phase 2 | 47 |
| Phase 3 | 42 |
| Phase 4 | 3 |
What is open in the Alexion Pharmaceuticals pipeline
17 recruiting of 162 indexed (10% open); 93 completed (57%).
Phase mix: 45 late (III/IV) vs 90 early (I/II) (early-phase heavy).
Top condition: Paroxysmal Nocturnal Hemoglobinuria (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alexion Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 162 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Alexion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 162 trials (± recruiting share)
- University of Vermont · 162 trials · 9% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
- Wayne State University · 163 trials · 13% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Vertex Pharmaceuticals Incorporated · 10% recruiting · 191 trials
- Bastyr University · 11% recruiting · 19 trials
- Corewell Health West · 11% recruiting · 38 trials
- Ethicon · 11% recruiting · 38 trials
Related
What to do with this Alexion Pharmaceuticals page
162 registered trials is a research-attention snapshot, not an endorsement of Alexion Pharmaceuticals or any single study.
- 17 of Alexion Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Paroxysmal Nocturnal Hemoglobinuria is the condition Alexion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Paroxysmal Nocturnal Hemoglobinuria trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alexion Pharmaceuticals pipeline card: 162 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.